Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma
Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma
复制标题
DOI：
10.1056/nejm199708213370804
复制
发表时间：
1997-08-21
影响因子：
158.5
通讯作者：
Hotta, T
中科院分区：
文献类型：
--
作者：
Ichikawa, A;Kinoshita, T;Hotta, T
背景p53基因突变与几种癌症的预后不良有关。我们研究了p53突变的预后重要性与侵略性B细胞lymphoma.Methods的患者，我们研究了存在或不存在可检测的p53突变的淋巴瘤细胞和化疗反应和总生存率在102例以前未经治疗的侵略性B细胞淋巴瘤患者之间的关系。p53基因的突变通过聚合酶链反应介导的单链构象多态性分析和直接sequencing.Results的102例侵袭性B细胞淋巴瘤，22（22%）涉及p53突变。携带p53突变的肿瘤患者（22例患者中的6例，27%）的完全缓解率显著低于携带野生型p53基因的患者（80例患者中的61例，76%）（P
Background Mutations of the p53 gene are associated with a poor prognosis in several types of cancer. We investigated the prognostic importance of p53 mutations in patients with aggressive B-cell lymphoma.Methods We examined the relation between the presence or absence of a detectable p53 mutation in lymphoma cells and the response to chemotherapy and overall survival in 102 previously untreated patients with aggressive B-cell lymphoma. Mutations of the p53 gene were identified by polymerase-chain-reaction-mediated analysis of single-strand conformation polymorphisms and by direct sequencing.Results Of 102 cases of aggressive B-cell lymphoma, 22 (22 percent) involved p53 mutations. The rate of complete remission was significantly lower in patients with a tumor carrying a p53 mutation (6 of 22 patients, 27 percent) than in those with the wild-type p53 gene (61 of 80 patients, 76 percent) (P